Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers. Immune thrombocytopenia (ITP ...

However, applying a conventional age-based testing threshold would have substantially reduced the number of patients identified. Restricting testing to patients diagnosed before age 50 would have ...

Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer. Theodore Wagener, PhD, founding ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival ...

The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on ...

CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, ...

The addition of carotuximab (ENV-105) to apalutamide (Erleada) significantly improved progression-free survival (PFS) ...

Among 102 patients with recurrent or metastatic head and neck squamous cell carcinoma evaluable for response, Dr Swiecicki reports a confirmed overall response rate (ORR) of 42% by a blinded ...

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study. Giada Bianchi, MD, discusses tailoring therapy in myeloma, ...

Adding aglatimagene besadenovec (CAN-2409) to external beam radiation therapy (EBRT) was associated with greater lymphocyte infiltration of prostate tissue and greater lymphocyte- ...

Broader community enrollment improves external validity by capturing patients with comorbidities and real-world treatment patterns, while familiarizing clinicians with toxicity management before ...